02/05/2022Published by Fondazione Gianni Bonadonna at 02/05/2022Categories Events UncategorizedA new screening platform to discover novel KRAS inhibitors
25/04/2022Published by Fondazione Gianni Bonadonna at 25/04/2022Categories Events UncategorizedA novel approach to target enhancer-addicted cancers
18/04/2022Published by Fondazione Gianni Bonadonna at 18/04/2022Categories Events UncategorizedPro-tumorigenic mechanisms of leukaemia
11/04/2022Published by Fondazione Gianni Bonadonna at 11/04/2022Categories Events UncategorizedPyrotinib plus capecitabine in breast cancer with brain metastases
04/04/2022Published by Fondazione Gianni Bonadonna at 04/04/2022Categories Events UncategorizedLenvatinib and pembrolizumab efficacy in endometrial cancer
28/03/2022Published by Fondazione Gianni Bonadonna at 28/03/2022Categories Events UncategorizedBreast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
21/03/2022Published by Fondazione Gianni Bonadonna at 21/03/2022Categories Events UncategorizedMEK inhibition enhances chemoimmunotherapy
14/03/2022Published by Fondazione Gianni Bonadonna at 14/03/2022Categories Events UncategorizedA new therapeutic strategy with selective N- glycosylation inhibitors?
07/03/2022Published by Fondazione Gianni Bonadonna at 07/03/2022Categories Events UncategorizedTargeted protein degradation to tackle ‘undruggable targets’
